Forum für Wissenschaft, Industrie und Wirtschaft

Hauptsponsoren:     3M 
Datenbankrecherche:

 

Metformin offers cardio benefits over sulfonylureas in diabetes

08.11.2012
A Vanderbilt study examining the impact of the two most commonly prescribed oral diabetes medications on the risk for heart attack, stroke and death has found the drug metformin has benefits over sulfonylurea drugs.

It was important to examine the cardiovascular impact of the more commonly used diabetes drugs after recent controversy surrounded another diabetes medication, rosiglitazone, because it was associated with an increased cardiac risk, said lead author, Christianne L. Roumie, M.D., MPH, assistant professor of Internal Medicine and Pediatrics. Smaller studies pointed to a potential advantage of taking the drug metformin but this study confirms this in a large population.

"We demonstrated that for every 1,000 patients who are using metformin for a year there are two fewer heart attacks, strokes or deaths compared with patients who use sulfonylureas. I think this reinforces the recommendation that metformin should be used as the first medication to treat diabetes," Roumie said.

The researchers looked at the charts of more than 250,000 veterans receiving care in Veterans Health Administration hospitals throughout the United States. The patients were started on oral therapy for their diabetes with either metformin or a sulfonylurea and followed for about a year. Results are in the Nov. 6 issue of Annals of Internal Medicine.

"Both drugs do a good job helping control diabetes and preventing nerve damage and eye disease associated with high sugar levels. We did this study because there was an important knowledge gap about whether metformin was superior to sulfonylureas for prevention of heart disease, stroke and death," said senior author Marie R. Griffin M.D., MPH, professor of Preventive Medicine.

The limitations of the study include that neither patient group was compared with diabetic patients who take no oral medications, and that the veteran patients were mostly men.

Metformin is already the recommended first-line therapy for those needing oral medication to control type 2 diabetes. The most common side effect is stomach upset, which can often be overcome by titrating the dosage up slowly. It has not been recommended that patients with kidney impairment take metformin, so sulfonylureas might be a better choice for those patients.

Roumie said this study suggests it might be prudent to take a second look at those patients who have been taking sulfonylureas to see if a switch to metformin might be recommended.

Craig Boerner | EurekAlert!
Further information:
http://www.vanderbilt.edu

Further reports about: Internal Medicine Medicine Metformin diabetes drug diabetes medication

More articles from Health and Medicine:

nachricht On track to heal leukaemia
18.01.2017 | Universitätsspital Bern

nachricht Penn vet research identifies new target for taming Ebola
12.01.2017 | University of Pennsylvania

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Textiler Hochwasserschutz erhöht Sicherheit

Wissenschaftler der TU Chemnitz präsentieren im Februar und März 2017 ein neues temporäres System zum Schutz gegen Hochwasser auf Baumessen in Chemnitz und Dresden

Auch die jüngsten Hochwasserereignisse zeigen, dass vielerorts das natürliche Rückhaltepotential von Uferbereichen schnell erschöpft ist und angrenzende...

Im Focus: Wie Darmbakterien krank machen

HZI-Forscher entschlüsseln Infektionsmechanismen von Yersinien und Immunantworten des Wirts

Yersinien verursachen schwere Darminfektionen. Um ihre Infektionsmechanismen besser zu verstehen, werden Studien mit dem Modellorganismus Yersinia...

Im Focus: How gut bacteria can make us ill

HZI researchers decipher infection mechanisms of Yersinia and immune responses of the host

Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...

Im Focus: Interfacial Superconductivity: Magnetic and superconducting order revealed simultaneously

Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.

While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...

Im Focus: Erforschung von Elementarteilchen in Materialien

Laseranregung von Semimetallen ermöglicht die Erzeugung neuartiger Quasiteilchen in Festkörpersystemen sowie ultraschnelle Schaltung zwischen verschiedenen Zuständen.

Die Untersuchung der Eigenschaften fundamentaler Teilchen in Festkörpersystemen ist ein vielversprechender Ansatz für die Quantenfeldtheorie. Quasiteilchen...

Alle Focus-News des Innovations-reports >>>

Anzeige

Anzeige

IHR
JOB & KARRIERE
SERVICE
im innovations-report
in Kooperation mit academics
Veranstaltungen

Künftige Rohstoffexperten aus aller Welt in Freiberg zur Winterschule

18.01.2017 | Veranstaltungen

Bundesweiter Astronomietag am 25. März 2017

17.01.2017 | Veranstaltungen

Über intelligente IT-Systeme und große Datenberge

17.01.2017 | Veranstaltungen

 
VideoLinks
B2B-VideoLinks
Weitere VideoLinks >>>
Aktuelle Beiträge

Der erste Blick auf ein einzelnes Protein

18.01.2017 | Biowissenschaften Chemie

Das menschliche Hirn wächst länger und funktionsspezifischer als gedacht

18.01.2017 | Biowissenschaften Chemie

Zur Sicherheit: Rettungsautos unterbrechen Radio

18.01.2017 | Verkehr Logistik